Daratumumab-induced in vivo immune modulation in relapsed and/refractory multiple myeloma patients treated with daratumumab-len-dex

被引：0
|
作者：
Giannotta, Claudia [1 ]
Ziccheddu, Bachisio [2 ]
D'Agostino, Mattia [3 ,4 ]
Bertuglia, Giuseppe [5 ]
Saraci, Elona [5 ]
Oliva, Stefania [5 ]
Bolli, Niccolo' [6 ]
Landgren, Ola [7 ]
Bruno, Benedetto [3 ,4 ]
Boccadoro, Mario [8 ]
Maura, Francesco [7 ]
Massaia, Massimo [1 ]
Larocca, Alessandra [5 ]
机构：
[1] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Mol Biotechnol Ctr Guido Tarone, Lab Blood Tumor Immunol, Turin, Italy
[2] Univ Miami, Coral Gables, FL 33124 USA
[3] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy
[4] Univ Turin, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
[5] Univ Turin, Azienda Osped Univ Citta Salute & Sci Torino, Div Ematol U, Myeloma Unit, Turin, Italy
[6] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Div Hematol & Stem Cell Transplantat, Milan, Italy
[7] Univ Miami, Myeloma Div, Sylvester Comprehens Canc Ctr, Miami, FL USA
[8] Cattedra Ematol, Hematol Div, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-392
引用
收藏
页码：S256 / S257
页数：2
相关论文
共 50 条
  • [1] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Blair, Hannah A.
    DRUGS, 2017, 77 (18) : 2013 - 2024
  • [2] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Hannah A. Blair
    Drugs, 2017, 77 : 2013 - 2024
  • [3] ECONOMIC EVALUATION OF DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Salazar, A.
    Guirant Corpi, L.
    Aguirre, A.
    Herrera, M.
    Chacon, C.
    VALUE IN HEALTH, 2018, 21 : S254 - S254
  • [4] Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary
    Callander, Natalie
    Tuchman, Sascha
    Chen, Christine
    White, Darrell
    Kotb, Rami
    Sutherland, Heather
    Sebag, Michael
    Baljevic, Muhamed
    Bensinger, William
    Leblanc, Richard
    Venner, Chris
    Bahlis, Nizar
    Rossi, Adriana
    Biran, Noa
    Sheehan, Heidi
    Saint-Martin, Jean-Richard
    Van Domelen, Dane
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael
    Lipe, Brea
    EJHAEM, 2021, 2 (01): : 56 - 65
  • [5] Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
    Galusic, Davor
    Krecak, Ivan
    Blaslov, Viktor
    Opara, Andela Krstulovic
    Valkovic, Toni
    Kinda, Sandra Basic
    BIOMEDICINES, 2025, 13 (01)
  • [6] Daratumumab, Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naive Relapsed Refractory Multiple Myeloma Patients
    Ouchveridze, Evguenia
    Singh, Chandandeep
    Atrash, Shebli
    Paul, Barry
    Mohan, Meera
    Alkharabsheh, Omar
    Afrough, Aimaz
    Cui, Wei
    Mahmoudjafari, Zahra
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2022, 140 : 7164 - 7165
  • [7] Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
    Pierceall, William E.
    Amatangelo, Michael D.
    Bahlis, Nizar J.
    Siegel, David S.
    Rahman, Adeeb
    Van Oekelen, Oliver
    Neri, Paola
    Young, Mary
    Chung, Weiyuan
    Serbina, Natalya
    Parekh, Samir
    Agarwal, Amit
    Thakurta, Anjan
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5895 - 5902
  • [8] Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd)
    Vishwamitra, Deeksha
    Mantis, Christine
    Haribhai, Dipica
    Uziel, Tamar
    Leverson, Joel D.
    Pauff, James M.
    Bueno, Orlando F.
    Maciag, Paulo C.
    Ross, Jeremy A.
    BLOOD, 2019, 134
  • [9] Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
    Usmani, Saad Z.
    Nahi, Hareth
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Chari, Ajai
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Luo, Man
    Liu, Kevin
    San-Miguel, Jesus
    BLOOD, 2019, 134 (08) : 668 - 677
  • [10] Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Hannah A. Blair
    Drugs, 2018, 78 : 397 - 397
12345